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SUMMARY. Coccidiosis remains a significant threat to the welfare of game farm–reared pheasants in the United States.
Although lasalocid has been demonstrated to be effective against pheasant specific coccidia, information regarding its safety in this
species is lacking. The purpose of this study was to gather data on the safety of lasalocid when fed to Chinese ring-necked pheasants
at one, two, and three times the recommended high dose of lasalocid used for prevention of coccidiosis in other poultry at three
times the normal treatment period. Pheasant chicks (approximately 1 day-old; n 5 160) were randomly blocked by sex into four
treatment groups and given their respective diets continuously for 6 wk. No significant differences were observed in overall feed
consumption, weight gain, feed conversion rates, clinical pathology measurements, or tissue gross and histopathologic evaluations
between controls and treatment groups associated with lasalocid administration. Based on the results of this study it appears that
lasalocid fed at the recommended rate of 125 ppm is safe in Chinese ring-necked pheasants.
RESUMEN. Evaluación de la seguridad del uso de la lasalocida en faisanes comunes (Phasianus colchicus).
La coccidiosis sigue siendo una amenaza importante para el bienestar de las aves de caza criadas en granja en los Estados Unidos.
Aunque la lasalocida ha demostrado ser eficaz contra las coccidias especı́ficas para los faisanes, no se cuenta con la información
referente a la seguridad en esta especie. El propósito de este estudio fue recopilar datos sobre la seguridad de la lasalocida
suministrada a los faisanes en una, dos y tres veces la dosis máxima recomendada de lasalocida utilizada para la prevención de la
coccidiosis en otras aves de corral en un periodo tres veces mayor al periodo de tratamiento normal. Ciento sesenta polluelos de
faisán de un dı́a de edad fueron asignados aleatoriamente en cuatro grupos de tratamiento bloqueados por sexo y administrando sus
respectivas dietas continuamente durante seis semanas. No se observaron diferencias significativas en el consumo del alimento
general, el aumento de peso, las tasas de conversión del alimento, las mediciones de patologı́a clı́nica, o en las evaluaciones
macroscópicas e histopatolœgicas de tejidos entre los controles y los grupos tratados, asociados con la administraciœn de la
lasalocida. Con base en los resultados de este estudio se deduce que la lasalocida proporcionada en el alimento a la tasa recomendada
de 125 ppm es segura en faisanes comunes.
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Abbreviations: FDA/CVM 5 U.S. Food and Drug Administration/Center for Veterinary Medicine; ppm 5 parts per million
Farm-reared Chinese ring-necked pheasants (Phasianus colchicus)
are routinely infected with coccidia such as Eimeria colchici, Eimeria
duodenalis, and Eimeria phasiani (5,8,10). Fatal infections are
highest between 2 and 6 weeks of age and may result in high
morbidity and mortality and consequently severe economic losses.
Options available for treatment of coccidiosis in pheasants are
limited, with amprolium (CoridH, Merial Limited, Duluth, GA)
being the only approved medication for prevention of disease (9,12).
Although safe and effective at 175 ppm, amprolium has a limited
species activity spectrum and resistance has been reported (11).
Lasalocid (AvatecH, Pfizer Animal Health, Madison, NJ) is a
carboxylic polyether ionophore that has been shown to be safe and
efficacious against species-specific coccidia that cause disease in
broiler chickens, growing turkeys, and chukar partridges. At
120 ppm, lasalocid has been shown to decrease oocyst shedding
and allow improved weight gain in infected pheasants when
compared to untreated pheasants (3,8). Before lasalocid can be
approved for clinical application, undesirable side effects that may
occur as a result of its use must be documented and reviewed by the
U.S. Food and Drug Administration/Center for Veterinary
Medicine (FDA/CVM). The objective of this study was to assess
the safety of lasalocid in Chinese ring-necked pheasants, to support
the addition of pheasants to the Avatec label. It was hypothesized
that continuous feeding of lasalocid at higher than recommended
levels for 6 wk would be toxic to Chinese ring-necked pheasants.
MATERIALS AND METHODS
Pheasants. One hundred sixty Chinese ring-neck pheasant chicks
were purchased from Oakwood Game Farm (Princeton, MN). There
were 80 males and 80 females. Pheasant chicks were 1 day old at study
initiation and 6 wk old at study termination.
Pheasant housing and maintenance. Pheasants were housed at the
poultry research facility at the Iowa State University Poultry Science
Farm (Ames, IA). No acclimation period was used, and pheasant chicks
were placed in the experiment on the day of arrival. Pheasants were
raised in floor pens that measured 1.22 3 1.22 3 1.22 m separated by
wire partitions. Heat lamps suspended approximately 0.35 m were used
to provide artificial heat and light for the pheasant chicks up to 2 wk of
age. Once heat lamps were removed, room lighting was the only source
of light for the pheasants. Pheasants were provided with approximately
16 hr of light and 8 hr of darkness per day. Wood shavings were used as
bedding and were replenished as needed to maintain a sanitary and
comfortable environment.DCorresponding author. E-mail: rgriffit@iastate.edu
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Treatment and control group layout. Pheasant chicks were blocked
by sex and randomly assigned to four test groups of 40 pheasants each
(20 males and 20 females). Eight pens (replicates) were used per test
group and each pen housed five pheasants. There were a total of 32 pens
of pheasants.
Test article and diet formulation. The basal diet used was a
commercial starter preparation, (Game Bird StartenaTM Purina Mills,
LLC, Gray Summit, MO), formulated to meet the nutritional
requirements of pheasants from 0 to 6 wk of age. Lasalocid (Avatec)
was obtained from Alpharma Inc. (Bridgewater, NJ) as a premix with
20% (199.54 g/kg) lasalocid sodium. Lasalocid was formulated for
mixing with the basal diet using the following formula:
Dose mg=kgð Þ|Weight of basal diet kgð Þ=
Concentration of lasalocid g lasalocid=g premixð Þ~
Test Article Dose gð Þof premix per 45:4 kg bag of premix
Approximately 0.5 kg of the medicated feed was collected from each
prepared batch and submitted to Alpharma Inc. for assay at study
initiation and at study termination.
Experimental design. There were four test groups in this
investigation. Table 1 shows the formulation of the four test group
diets. No lasalocid was added to the diet fed to the pheasants in test
group one, the controls. Pheasants in test groups two, three, and four
were fed the basal diet with approximately 125, 250, and 375 ppm
lasalocid added, respectively. These doses were equivalent to 13, 23,
and 33 the approved dose of lasalocid in broiler or fryer chickens,
growing turkeys, and chukar partridges. Fresh feed was provided to the
pheasants once daily for 6 wk. Water was provided ad libitum via
automatic drip tubes. Blinding was maintained by ensuring that persons
who were involved at each level of clinical or pathologic evaluations had
no knowledge of dosing. All phases of this study were conducted under
Good Laboratory Practices (21 CFR Part 58) guidelines for nonclinical
laboratory studies, and were approved by the Institutional Animal Care
and Use Committee of Iowa State University. Critical phases were
monitored by quality assurance personnel appointed by the Minor Use
Animal Drug Program, National Research Support Project-7 (NRSP-7).
Clinical observations. Study inclusion physical examinations were
conducted by a veterinarian on each pheasant on day 0, and only normal
and healthy pheasant chicks were included in the study. Pheasants were
observed twice daily throughout the study to determine their general
appearance as well as monitor consistency of fecal output, death, and/or
normal conditions. A veterinarian confirmed any unusual observations.
Moribund and/or dead pheasants were removed and necropsied. The
chicks were weighed as a group at the time of placement into pens and
individually at euthanasia at 6 wk of age.
Feed consumption and feed efficiency. Fresh feed was weighed daily
prior to being fed to pheasants. Feed remaining in feed containers or that may
have inadvertently spilled during the day or night was noted in the morning,
weighed and discarded. Overall feed consumption and feed conversion rates
were determined and reported as average of the pen at the end of the study.
The following formula was used to calculate adjusted feed conversion rate:
Total f eed disappearance=
total terminal pen bird weightð½
zall dead and removed bird weightsÞ
{total bird weights in the pen at day 0
Total feed disappearance (feed consumption) was defined as the sum
of all feed additions to a pen minus the sum of all feed weighed back
from that pen and the estimated or actual wastage.
Clinical pathology. At 6 wk, pheasants were randomly sacrificed by
direct intramuscular injection of pentobarbital solution (BeuthanasiaH,
Intervet Schering-Plough, Summit, NJ) into the left breast muscle. As
soon as the birds were unconscious and prior to cardiac arrest,
approximately 2 ml of blood was collected via the vena cava or heart
chamber. The blood was divided between EDTA and heparinized
vacutainer tubes and submitted to the Iowa State University, Veterinary
Clinical Pathology Laboratory for hematology and serum biochemistry
analyses. The following hematology variables were determined: red
blood cell count (RBC); packed cell volume (PCV); mean corpuscular
volume (MCV); white blood cell count (WBC); and heterophil,
eosinophil, lymphocyte, monocyte, and thrombocyte counts. The
following serum biochemistry values were determined: glucose, total
protein (TP), albumin, creatine kinase, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), gamma-glutamyl transferase
(GGT), calcium, phosphorous, sodium, potassium, chloride, magne-
sium, amylase, uric acid, lactate dehydrogenase (LDH), alkaline
phosphatase (ALP), total bilirubin, cholesterol, and globulin.
Organ weights, necropsy, and histopathology. Organ weights were
obtained on heart, liver, spleen, and thymus of the sacrificed birds. The
following organs and tissues were examined grossly and histologically for
any lesions or abnormalities: skin, eyes, liver, kidney, heart, lungs,
trachea, adrenal gland, pancreas, esophagus, crop, spleen, proventriculus,
ventriculus, intestines (upper, middle, and cecum), bursa of Fabricius,
ovaries and oviducts, testes, bone, bone marrow, thyroid gland, thymus,
parathyroid gland, brain, spinal cord, and pituitary body. If lesions were
noted on gross necropsy, a full description was made and tissues
collected for histologic examination. If no lesions were present, a
representative sample of tissues was collected for histologic examination.
The selected tissues were preserved in 10% neutral buffered formalin
and prepared as paraffin-embedded sections on glass microscopic slides.
Table 1. Test group diet analyses reported by Alpharma Inc.
Diet Target dose g/t (ppm) Pre-trial lasalocid analysis g/t (ppm) Post-trial lasalocid analysis g/t (ppm)
Control 0 (0) ,0.5 (0) ,0.5 (0)
13 113 (125) 133.6 (147) 110.3 (122)
23 204 (250) 231.8 (256) 244.7 (270)
33 340 (375) 424.7 (468) 272 (300)
Table 2. Test group means (SD) for live weights, organ weights, overall weights, feed consumption, and feed conversion rates.
Variable Control, mean (SD) 13 Group, mean (SD) 23 Group, mean (SD) 33 Group, mean (SD)
Beginning body weight (g) 90.38 (2.77) 90.13 (1.73) 93.50 (4.72) 88.63 (5.15)
Ending body weight (g) 358.50 (43.95) 368.41 (46.80) 372.85 (47.44) 362.48 (51.30)
Feed consumption (g) 3992.63 (254.05) 4024.25 (385.63) 4054.00 (456.73) 4114.38 (333.66)
Feed conversion rate 2.35 (0.08) 2.36 (0.09) 2.35 (0.07) 2.39 (0.07)
Liver weight (g) 7.88 (1.07) 8.28 (1.04) 8.65 (1.18) 8.61 (1.30)
Heart weight (g) 1.69 (0.29) 1.81 (0.28) 1.78 (0.27) 1.80 (0.27)
Spleen weight (g) 0.25 (0.08) 0.33 (0.14) 0.32 (0.13) 0.34 (0.12)
Thymus weight (g) 1.22 (0.40) 1.34 (0.39) 1.36 (0.30) 1.37 (0.44)
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Tissue sections stained with hematoxylin and eosin were examined by
light microscopy. Necropsy and histopathologic examinations were
performed by a board-certified veterinary anatomic pathologist.
Data analyses. Statistical analyses were performed using SAS
Enterprise Guide statistical software (version 4.3; SAS Institute, Inc.,
Cary, NC, USA). A mixed effect two-way analysis of variance was
performed on the variables live weights, organ weights, feed consumption
data, serum chemistry, and hematology data. Least square means were
used to compare the treated test groups to the control test groups. All
statistical tests were conducted at a level of 0.05 for this publication, but a
level of 0.10 was required to meet FDA/CVM protocol specifications.
RESULTS
Diet analyses. Analyses performed on each dietary treatment
group to confirm the target test article composition are shown in
Table 1. Lasalocid was incorporated into three out of four test group
diets. Beginning and ending trial composition for diets 2, 3, and 4
were within 20% of the targeted dose.
Pheasant observations, morbidity, and mortality. One hundred
fifty-eight out of 160 pheasants received their intended doses for the
entire 6 wk. Two pheasants were observed to be moribund on days
17 (23 group) and 27 (33 group), respectively, and these were
humanely euthanatized. Tissue evaluations of these pheasants
revealed that the first bird had a generalized bacterial infection
and the second bird had a dislocation of the spinal cord between
cervical vertebrae C3 and C4. These deaths were not attributed to
lasalocid administration. All other pheasants remained clinically
healthy based on a normal general appearance and normal fecal score
for the duration of the study. None of the signs of lasalocid toxicity
described in other poultry were observed. The 1.25% mortality rate
observed was within historical values of the facility and statistical
analyses were not necessary for the variables morbidity and mortality.
Live weights, feed consumption and feed conversion rates.
Test group means are summarized in Table 2. All pheasant groups
gained weight over the course of the study and consumed
approximately equal amounts of feed. Mean ending weights were
slightly higher for each treatment group compared to controls, but
these were not significant (P $ 0.05).
Clinical pathology. Hematology and serum biochemistry
parameter test group means are summarized in Table 3. There were
no significant differences in any of the clinical pathology variables
between treatment and control groups (P $ 0.05).
Tissue evaluations. There were no differences in respective mean
terminal organ weights between treatment and control groups (P $
0.05). No treatment-related gross lesions were observed on any of the
pheasants. Occasionally, mild focal heterophilic and lymphocytic
infiltrates were seen microscopically on various tissues including
myocardia, kidneys, lungs, and spleens. These were evenly distributed
amongst the test groups and not associated with lasalocid adminis-
tration. One pheasant (33 group) had moderate subacute myocardial
hemorrhage, necrosis, and mineralization of the myocardium.
DISCUSSION
In general, lasalocid is safe in poultry if given at recommended
inclusion rate in feed. Lasalocid is used as a preventive for
coccidiosis, not a therapeutic treatment of infections. Toxic effects
described for older chickens and turkeys are commonly encountered
as a result of feed mixing errors (1,2,6,13). These are due to a cellular
dysfunction because lasalocid carries ions across host cell surface
membranes disrupting normal physiologic gradients (4). Depending
on the severity and duration of exposure, the effects of lasalocid
exposure may be reversible once removed from feed (7). Feeding
Table 3. Test group means (SD) from clinical pathology sample testing performed in controls and pheasants treated with lasalocid sodium.
Variable (units) Control mean (SD) 13 Mean (SD) 23 Mean (SD) 33 Mean (SD)
RBC (3106/ml) 3.05 (0.52) 2.87 (0.41) 2.77 (0.41) 2.72 (0.31)
PCV (%) 35.86 (2.44) 34.30 (2.17) 34.34 (2.89) 33.87 (2.45)
MCV (fl) 120.27 (17.01) 121.85 (17.43) 126.23 (17.62) 125.60 (11.85)
WBC (3103/ml) 9.07 (4.96) 8.24 (4.45) 9.4 (4.33) 11.17 (9.38)
Heterophils (3103/ml) 2.81 (3.27) 1.99 (2.43) 2.01 (2.23) 3.86 (6.80)
Eosinophils (3103/ml) 0.05 (0.09) 0.07 (0.10) 0.07 (0.12) 0.08 (0.13)
Basophils (3103/ml) 0.49 (0.42) 0.60 (0.32) 0.58 (0.35) 0.63 (0.39)
Lymphocytes (3103/ml) 5.60 (3.22) 5.45 (3.29) 6.39 (2.72) 6.04 (3.29)
Monocytes (3103/ml) 0.20 (0.21) 0.17 (0.16) 0.34 (0.48) 0.56 (1.24)
Glucose (mg/dl) 344.60 (26.32) 344.05 (36.76) 349.26 (30.48) 340.75 (25.77)
TP (mg/dl) 2.82 (0.24) 2.84 (0.23) 2.86 (0.26) 2.92 (0.46)
Albumin (mg/dl) 1.44 (0.15) 1.42 (0.10) 1.43 (0.13) 1.42 (0.13)
Creatine kinase (IU/L) 3376.40 (941.28) 3395.92 (1379.59) 3199.92 (926.82) 2896.08 (801.91)
AST (IU/L) 402.43 (93.11) 371.47 (57.27) 362.38 (42.79) 374.05 (48.93)
ALT (IU/L) 7.33 (6.12) 6.87 (3.24) 5.49 (1.90) 6.55 (4.21)
GGT (IU/L) 4.20 (1.70) 4.08 (1.94) 3.74 (1.73) 3.93 (1.56)
Calcium (mg/dl) 10.01 (0.57) 9.88 (0.94) 10.37 (0.58) 10.29 (0.87)
Phosphorus (mg/dl) 9.76 (1.91) 9.19 (1.98) 9.20 (1.28) 8.40 (0.92)
Sodium (mEq/L) 153.33 (3.00) 152.44 (2.16) 153.13 (2.96) 152.93 (2.53)
Potassium (mEq/L) 4.26 (1.54) 4.08 (1.50) 3.55 (0.92) 3.43 (0.74)
Chloride (mEq/L) 112.08 (2.15) 112.13 (2.32) 111.56 (3.00) 111.93 (2.68)
Magnesium (mg/dl) 2.53 (0.27) 2.42 (0.30) 2.52 (0.28) 2.40 (0.23)
Amylase (mg/dl) 2582.83 (856.96) 2607.03 (680.19) 2421.33 (657.68) 2438.48 (627.80)
Uric acid (mg/dl) 20.41 (8.47) 15.12 (6.07) 18.43 (6.81) 16.06 (7.87)
LDH (IU/L) 776.25 (328.70) 683.92 (174.04) 660.42 (136.33) 649.60 (196.99)
ALP (IU/L) 1286.68 (269.31) 1205.21 (242.75) 1211.74 (221.95) 1044.75 (259.68)
Total bilirubin (mg/dl) 0.21 (0.10) 0.25 (0.15) 0.26 (0.17) 0.26 (0.19)
Cholesterol (mg/dl) 104.23 (14.94) 111.55 (13.58) 108.18 (15.88) 112.08 (16.71)
Globulin (mg/dl) 1.36 (0.20) 1.42 (0.18) 1.78 (2.05) 1.49 (0.44)
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lasalocid for 6 wk at dietary levels up to 375 ppm was well tolerated,
and signs reported in other poultry were not seen. The microscopic
changes suggestive of lasalocid toxicity seen in the single pheasant were
likely incidental since no other pheasants in this group showed similar
lesions. The pheasant weighed 316 g (group mean was 362.48 g) and
had appeared clinically healthy, its clinical pathology parameters were
within established reference ranges, and no other tissue gross or
microscopic lasalocid-related lesions were seen.
As part of the approval process, lasalocid must be shown in controlled
trials to be safe at the claimed effective dose and progressively higher
doses, for an extended period of time beyond the duration it would
ordinarily be used. Information regarding any adverse reactions,
including death, associated with these overdoses or increased duration
of administration must be documented and reported to FDA/CVM.
Based on physical, clinical pathologic, and tissue evaluations (gross and
microscopic), we were unable to demonstrate adverse effects of feeding
lasalocid continuously to Chinese ring-necked pheasants at a rate of at
least three times the effective dose of 125 ppm.
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